Abiopharma

🔍 Landry Allison (Director)

Company: QXO, Inc. (QXO)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 12,111 shares of Common Stock, $0.00001 par value (Direct)
  Date: 2026-05-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,105.00 | transaction_form_type: 4
• Acquired 9,274 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,274.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Sold 12,111 shares of Restricted Stock Units (Derivative)
  Date: 2026-05-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive, upon settlement, one share of Common Stock.
• F2: The RSUs vest in full on the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service as a director of the Issuer.
• F3: On May 12, 2025, the Reporting Person was granted RSUs that vested and settled in full on the date of the Issuer's 2026 Annual Meeting of Stockholders.